Filing Details

Accession Number:
0001209191-23-054635
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-07 20:42:39
Reporting Period:
2023-11-03
Accepted Time:
2023-11-07 20:42:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1534133 Calcimedica Inc. CALC Pharmaceutical Preparations (2834) 452120079
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1576244 W Eric Roberts C/O Calcimedica, Inc.
505 Coast S. Blvd. #202
La Jolla CA 92037
Chief Business Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-11-03 3,700 $2.77 20,287 No 4 P Direct
Common Stock Acquisiton 2023-11-03 11,249 $2.83 33,494 No 4 P Indirect By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Indirect By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 5,223 Indirect By FMTC Custodian - Roth IRA FBO Eric W. Roberts
Common Stock 10,661 Indirect By IRA Financial Trust Company CFBO Eric W. Roberts
Common Stock 356,989 Indirect By Valence Investments SPV IV, LLC
Common Stock 66,228 Indirect By Valence Investments SPV V, LLC
Common Stock 316,109 Indirect By Valence Investments SPV VI, LLC
Footnotes
  1. The weighted average purchase price for the transaction reported was $2.77, and the range of prices were between $2.70 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
  2. The weighted average purchase price for the transaction reported was $2.831, and the range of prices were between $2.67 and $2.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
  3. The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.